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significant differences either in safety or in efficacy. The third 
controlled trial investigated the clinical efficacy of PHMB 
compared to placebo in the treatment of human papilloma 
virus. Patients treated with PHMB daily for up to 16-weeks 
showed significantly higher (52%) clearance of genital warts 
as compared to patients treated with placebo (4%).  Conclu-
sion: PHMB may be a clinically effective alternative for the 
treatment of BV and human papilloma virus. Although 
PHMB-based antiseptics are available since the late 90s, con-
trolled trials to investigate its clinical potential for antiseptic 
treatment are scant. Clinical use of antiseptics for the treat-
ment of infectious diseases should be explored and support-
ed further.  Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 The genital tract is an ecosystem for a multiplicity of 
microorganisms which have to be maintained in a fragile 
balance. If this balance is disturbed, infection may occur. 
Infectious diseases of the genital tract caused by bacteria, 
fungi, parasites, and viruses are a worldwide issue and are 
highly evidenced to impair somatic functions including 
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 Abstract 
 Background: In clinical practice, treatment of genital tract 
infections is based on administration of either antibiotics or 
antiseptics. While antibiotics may be applied systemically or 
topically, antiseptics may be applied only topically. In case of 
bacterial vaginosis (BV), antibiotic therapy may often be lim-
ited and side effects due to systemic administration may de-
velop. Polihexanide (PHMB) is a promising option for the top-
ical treatment of genital tract infections, in particular BV and 
vaginitis.  Method: A systematic search for publications on 
the use of PHMB for the treatment of genital infections in 
two electronic databases was performed. Titles, abstracts 
and citations were imported into a reference database. Du-
plicates were removed and two reviewers assessed each 
identified publication separately.  Results: Among a total of 
204 references, 3 prospective randomized trials were identi-
fied. Two trials treated BV infections with PHMB in compari-
son to clindamycin as antibiotic standard therapy with no 
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reproduction  [1, 2] . Additionally, the vaginal flora may be 
a source for surgical site infections  [3] , urogenital tract 
infections during pregnancy  [4] , and newborn infections 
including an increased risk of preterm birth  [5, 6] .
 Mycoplasma hominis is known to decrease fertility in 
males  [7] , whereas  Mycoplasma genitalium and  Chlamy-
dia trachomatis are responsible for infertility in males 
and females  [8, 9] . Equally important are gonococcal in-
fections which can cause urethritis, proctitis, cervicitis, 
and pelvic inflammatory disease with long-term effects 
such as infertility, ectopic pregnancy, and chronic pelvic 
pain  [10] . Enterobacteriaceae like  Escherichia coli or  En-
terococcus faecalis are the most common causes of non-
sexually transmitted infections  [2] .  Pseudomonas aerugi-
nosa as well as Gram-positive cocci that commonly
colonize the male urethra can cause prostatitis and
epididymitis and consecutively impair fertility  [11] .  Can-
dida albicans was associated with male infertility because 
of an inhibitory effect on human sperms  [12] . In the fe-
male genital tract,  C. albicans is a common commensal 
but may also cause vaginitis and cervicitis  [2] . Toxin-pro-
ducing  Staphylococcus aureus strains have been identi-
fied as underlying pathogens for the development of vag-
inal menstrual toxic shock syndrome  [13–15] . Viral geni-
tal tract infections are mostly caused by herpes viruses, 
human papilloma viruses (HPV), and human immuno-
deficiency viruses (HIV) either due to the virus itself or 
to side effects.
 Bacterial vaginosis (BV) is the most common disorder 
of the vaginal flora, caused by different microbial species, 
with a prevalence of 5–30% in adult females  [16–18] . BV 
is associated with an increased risk of acute upper genital 
tract infection  [19, 20] . Vaginitis is the most common gy-
necologic diagnosis secondary to BV  [21] , vulvovaginal 
candidiasis  [22] , or trichomoniasis  [23] .
 Infectious genital tract diseases are commonly treated 
with antibiotics such as clindamycin or metronidazole 
 [24] . Today, antimicrobial chemotherapy is increasingly 
complicated by progressive antibiotic resistance  [25] . 
Moreover, new insights into the structure and function of 
the colonization of the vagina help to explain why antibi-
otic treatment is only of limited use in infections involv-
ing microbial biofilms. The treatment of genital tract in-
fections, in particular vaginosis and vaginitis, is therefore 
still a great challenge. Compared to oral antibiotic thera-
py, local treatment of genital tract infections shows less 
systemically side effects like nausea, vomiting, and taste 
perversion  [26, 27] .
 Modern antiseptics are an excellent alternative to an-
tibiotic treatment, provided that they combine a broad 
antimicrobial spectrum with low toxicity, high tissue 
compatibility, low or missing adsorption, and good ap-
plicability. Therefore, antiseptics are the first option for 
the treatment of local microbial infections.
 In the past, chlorhexidine digluconate (CHX) was 
used as a general vaginal antiseptic for over three decades 
 [28] . However, hyperkeratosis, ulceration, dysplasia, and 
a significant increase in DNA damages by CHX were ob-
served in rat experiments  [29, 30] . Additionally, concen-
tration-dependent CHX significantly inhibits wound 
healing and granulation  [31, 32] , which corresponds with 
the cytotoxic effect on osteoblasts and odontoblast-like 
cells  [33, 34] . Moreover, degradation during storage may 
release the carcinogen 2-chloroanline from low-grade 
CHX  [35] .
 Therefore, other antiseptics like PHMB  [36] and oc-
tenidine  [37] have moved into the focus of antiseptic 
treatment. While PHMB is a structural sibling of CHX, 
it lacks many of its drawbacks because of the lack of 
2-chloroanaline in the molecular structure of PHMB.
 Polihexanide is well tolerated when used topically on 
skin, wounds  [38] , eyes  [39, 40] , and vaginal mucous 
membrane  [41] . Only a negligible allergic risk, very low 
toxicity, and no adsorption of PHMB have been described 
 [36] . Its tissue compatibility and biocompatibility is much 
better than that of CHX in vitro. Because of the addition-
ally higher antimicrobial efficacy, PHMB achieved a bet-
ter biocompatibility index than chlorhexidine and should 
be preferred  [42] . Additionally, PHMB significantly stim-
ulates wound healing  [43] and there is no indication of 
any mutagenicity or carcinogenicity of PHMB in vitro or 
in vivo  [38] .
 The efficacy of PHMB against infected wounds, pros-
theses, carcinomas, and methicillin-resistant  S. aureus 
(MRSA) in vivo has been extensively studied in different 
controlled clinical studies. The antimicrobial activity of 
PHMB based on its exclusive interaction with acidic, neg-
atively charged phospholipids in the bacterial membrane 
leads to increased fluidity, permeability, and loss of integ-
rity, followed by the death of the organism  [44–47] . Trans-
ferred to the cytoplasm it leads to disruption of the bacte-
rial metabolism. Because neutral phospholipids are only 
slightly affected, PHMB has a low toxicity against human 
cells  [38, 48, 49] . PHMB binds to cellular surfaces which 
is why it also has a sustained effect over hours  [39, 50] .
 PHMB is commercially available in many formula-
tions and for different indications including wound anti-
sepsis, rinsing, and decolonization of unwanted organ-
isms (e.g. MRSA) to name only a few. For genital treat-
ment, PHMB is patented as a single-dose, isotonic topical 
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solution (Monogin  ; Lo.Li. Pharma S.r.l., Rome, Italy). 
The purpose of this work is to review the existing litera-
ture on the antiseptic polihexanide (polyhexamethylene 
biguanide; PHMB) for the treatment of genital tract in-
fections.
 Methods 
 A systematic search for manuscripts published in any lan-
guage in the two electronic databases Pubmed and ISI Web of Sci-
ence was performed. The following syntax for literature searches 
in both databases was used:
 – Genital tract infection and PHMB or polihexanide or poly-
hexamethylene biguanide 
 – Vaginosis and PHMB or polihexanide or polyhexamethylene 
biguanide 
 – Vaginitis and PHMB or polihexanide or polyhexamethylene 
biguanide 
 No other limits were used. Bibliographies of manuscripts were 
screened for additional sources and an additional manual search 
was done.
 Studies were included on the basis of four criteria: disease, 
therapy, study design, and outcome. The diseases of interest were 
genital tract infections, especially vaginosis and vaginitis. The 
therapy of interest was treatment with PHMB. Primarily, in vivo 
studies and clinical studies were selected. Additionally, in vitro 
studies were considered to emphasize the efficacy against the dis-
ease-causing pathogen. The outcome of interest was the compar-
ison of PHMB treatment with a placebo or standard therapy.
 All relevant titles, abstracts, and citations were imported into 
a reference database. Duplicates were removed and two reviewers 
independently assessed each publication separately. Differences 
in opinion were discussed among all authors and the final deci-
sion was made by means of open consensus. Both reviewers inde-
pendently abstracted data from all selected studies.
 Results 
 The search results are shown in a flow diagram ( fig. 1 ). 
A total of 204 references were identified from the search-
es of the electronic databases. After omitting 138 dupli-
cate references, 66 original references were further ana-
lyzed. Overall, 21 potentially eligible studies were identi-
fied. The search resulted in one further study. Nineteen 
references were excluded after review of the full text. The 
3 eligible studies identified
138 duplicate records removed
21 potentially eligible studies
identified
19 failed to meet the inclusion
criteria
1 record identified through
a manual search
45 excluded using the published
abstracts and titles because of the
type of intervention and/or 
nonrelevance
66 records identified for initial
screening of titles and abstracts
204 records identified from
electronic database searches
 Fig. 1. Flow diagram outlining the litera-
ture search and review of the studies. 
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three remaining references were prospective randomized 
trials. In two trials, BV infections were treated with 
PHMB in comparison to clindamycin as standard thera-
py. The third trial investigated HPV patients treated with 
PHMB or a placebo in a randomized controlled study ( ta-
ble 1 ).
 In vitro Studies 
 The broad antimicrobial efficacy of PHMB against 
microorganisms frequently causing genital tract infec-
tions has been repeatedly shown in vitro. PHMB was ef-
fective against planktonic  E. coli and  S. aureus as well as 
 P. aeruginosa in suspension and biofilms  [37–42, 51–53] . 
In addition, PHMB was also effective against  E. faecalis 
and  C. albicans  [54] , as well as against intracellular bac-
teria such as  Chlamydia sp. and  Neisseria sp.  [52] , and 
protozoa such as  Acanthamoeba  [53] .
 The virocidal in vitro efficacy of PHMB was investi-
gated in two references. It was shown that 0.01% PHMB 
is effective against herpes viruses in vitro  [58] . Krebs et 
al.  [59] found a modest antiviral efficacy against cell-free 
and cell-associated HIV-1. Furthermore, they found that 
PHMB inhibited binding and entry of the virus.
 Clinical Studies 
 Minozzi et al.  [57] compared the efficacy of a single-
dose PHMB solution (Monogin) versus a 7-day clindamy-
cin cream treatment against BV in a multi-center, ran-
domized, single-blind and parallel-group study which en-
rolled 740 patients. Twenty-one to 30 days after the start 
of the study, the authors found no significant (95% CI,
p = 0.386) differences between both therapy regimes 
 either in safety or in efficacy. Safety was investigated by 
monitoring treatment-emergent adverse events (e.g. uri-
nary tract infection) throughout the study. Namely, 30.4% 
of all PHMB-treated patients and 26.8% of clindamycin-
treated patients had an adverse event, with no statistically 
significant difference. The efficacy was analyzed in a per-
protocol group with 347 patients. Cure of BV in the per-
protocol group was evaluated by frequencies of ‘investiga-
tor cure’ (requirement for additional therapy: 89.1% of the 
PHMB group, 86.4% of the clindamycin group achieved 
cure), ‘clinical cure’ (conservative symptomatic measure: 
64.3% of the PHMB group, 63.2% of the clindamycin 
group achieved cure), ‘Nugent cure’ (diagnostic evalua-
tion: 56.5% of the PHMB group, 57.7% of the clindamycin 
group achieved cure), and ‘therapeutic cure’ (symptom-
atic, interpretive, and diagnostic measures: 42.1% of the 
PHMB group, 45.6% of the clindamycin group achieved 
cure). Pertaining to the results, it seems that a single dose 
of PHMB is statistically equivalently effective to 7 daily 
doses of clindamycin for the treatment of BV.
 Gerli and di Renzo  [41] investigated patients treated 
with the same regimen (PHMB, n = 59; clindamycin, n = 
51) and concluded that mono-dose PHMB treatment 
should be the therapy of choice for BV.
 Marelli et al.  [63] showed in a prospective, double-
blind, randomized placebo trial that PHMB is effective 








Among 110 BV patients, the efficacy of a single-dose 
PHMB vaginal gel versus a 7-day clindamycin cream 
treatment against BV was compared
The efficacy of mono-dose 
PHMB treatment was similar to 
7-days clindamycin cream 
treatment
Marelli





HPV patients (n = 140), who applied PHMB daily for up 
to 16 weeks, were cleared of warts in 52% of cases (warts 
clearance in the placebo group, 4%). In a 12-week 
treatment-free follow-up period, wart recurrence was 
investigated. The recurrence rate after a 12-week 
treatment-free follow-up period was 19% in the PHMB 
group and 0% in the placebo group
PHMB is effective for the 
treatment of genital papilloma 
virus infections
Minozzi





Among 740 BV patients, the efficacy of a single-dose 
PHMB solution (Monogin) versus a 7-day clindamycin 
cream treatment against BV was compared
There were no significant 
differences between the two 
therapy regimes either in safety 
or in efficacy
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for the treatment of genital papilloma virus infections. 
Patients who applied PHMB daily for up to 16 weeks were 
significantly (p  ! 0.0001) more frequently cleared of 
warts (52%) as compared to patients in the placebo group 
(4%). In a 12-week treatment-free follow-up period, wart 
recurrence was investigated. The recurrence rate after the 
12-week treatment-free follow-up period was 19% in the 
PHMB group and 0% in the placebo group.
 Discussion 
 Genital tract infections are a serious challenge in gy-
necology as well as in urology. In the last decade it has 
become increasingly clear that antimicrobial chemother-
apy is limited by an increasingly prevalent antibiotic re-
sistance. Additionally, frequent and inappropriate use of 
antibiotics promotes resistance even further. With the 
availability of new antiseptic compounds with a broad 
antimicrobial spectrum, provided in easy-to-use and 
well-tolerated formulations, local treatment is expected 
to become more and more important in genital tract ther-
apy of localized limited infections.
 PHMB is a modern antiseptic that combines a broad 
antimicrobial spectrum with low toxicity and without 
long-term risks, and with high tissue compatibility, no 
reported adsorption, and good applicability as solution, 
gel, ointment, or foam  [37] . The modes of action make the 
development of resistance to PHMB highly unlikely. Ac-
tually, no bacterial resistance has been described in vitro 
or from clinical or environmental samples  [69] . The an-
timicrobial efficacy of PHMB is not impaired by protein 
and blood  [71] . The most interesting feature of PHMB is 
its outstanding relation between antimicrobial efficacy 
and low cytotoxicity and exceptional tissue compatibility 
that has been repeatedly described by independent re-
searchers in vitro, in animal models, and in controlled 
clinical studies and case reports. At low concentrations, 
PHMB even seems not only to be nontoxic but also to 
have a positive effect on the proliferation of human kera-
tinocytes that promotes wound healing  [60–62] . It is ac-
tually one of the most promising antiseptic substances 
and has been used in medicine for many indications for 
over 20 years.
 Although the efficacy of PHMB against typical genital 
tract pathogens has been repeatedly demonstrated, the 
number of actual clinical studies published on the topic 
is limited because the introduction of PHMB in clinical 
practice (except in wound antisepsis) only started in the 
last decade. Identified studies show the clinical effective-
ness of PHMB and go along well with results from in vivo 
studies and clinical data from other indications, e.g. 
wound infections and treatment of acanthamoeba kera-
titis  [36] . Minozzi et al.  [57] and Gerli et al.  [41] compared 
the efficacy of a single-dose PHMB solution (Monogin) 
versus 7-day clindamycin cream treatment against BV 
and found no significant differences between the two 
therapy regimes in either safety or efficacy. The mecha-
nism of action of clindamycin is based on the inhibition 
of protein synthesis by binding to the 50S subunit of the 
bacterial ribosome, resulting in a mostly bacteriostatic 
effect. Therefore, the efficacy depends mainly on the pe-
riod of time during which the effective concentration is 
above the minimum inhibitory concentration of the 
pathogen. Because both agents were self-administered by 
the patients, the efficacy depends also on the compliance, 
which is commonly better in cases of single treatment 
with PHMB. 
 Even the antiviral efficacy against genital papilloma-
virus could be demonstrated in a clinical trial  [63] . In the 
past, CHX or antibiotics were often used for the treat-
ment of genital tract infections. The evidence available 
today, though limited, indicates that even a single dose of 
PHMB is comparable to a 7-day antibiotic course but has 
no unwanted effects like induction of antimicrobial resis-
tance.
 Until now, a final evaluation of PHMB in comparison 
to other genital tract antiseptics, e.g. CHX, has not been 
possible because no studies comparing both substances 
are available. Due to the better tissue compatibility of 
PHMB compared with CHX, the in vitro effectiveness of 
PHMB in the presence of a bio-burden, the primary de-
creased susceptibility of enterococci strains against CHX 
 [64] , and the R-plasmid-coded CHX resistance in vitro 
 [65–67] with possible cross-resistance against antibiotics 
 [68] , such studies would be highly appreciated as final 
evidence for the superiority of treatment of genital tract 
infections by PHMB as previously shown for other indi-
cations.
 Conclusion 
 PHMB may be a clinically effective alternative for the 
treatment of BV and HPV. Although PHMB-based anti-
septics have been available since the late 90s, controlled 
trials to investigate its clinical potential for antiseptic 
treatment are scant. Clinical use of antiseptics for the 
treatment of infectious diseases should be explored and 
supported further.
 Clinical Use of PHMB for Genital Tract 
Infections 
 Skin Pharmacol Physiol 2012;25:298–304  303
 Acknowledgment 
 Funding for this research was provided by Lo.Li Pharma.
Disclosure Statement
The authors have no conflicts of interest that are directly rel-
evant to the content of this study.
 
 References 
 1 Larsen B: Vaginal f lora in health and disease. 
Clin Obstetr Gynecol 1993; 36: 107–121. 
 2 Pellati D, Mylonakis I, Bertoloni G, et al: 
Genital tract infections and infertility. Eur J 
Obstetr Gynecol Reprod Biol 2008; 140: 3–11. 
 3 Larsson PG, Carlsson B: Does pre- and post-
operative metronidazole treatment lower 
vaginal cuff infection rate after abdominal 
hysterectomy among women with bacterial 
vaginosis? Inf Dis Obstetr Gynecol 2002; 10: 
 133–140. 
 4 Shopova E, Nikolov A, Dimitriv A: Link be-
tween the state of vaginal f lora and the devel-
opment of uroinfection during pregnancy 
(in Bulgarian). Akush Ginekol 2005; 44: 38–
39. 
 5 Tolosa JE: Chlorhexidine antisepsis to re-
duce neonatal mortality must be adopted 
globally. Ped Inf Dis J 2006; 25: 676–679. 
 6 Lamont RF, Taylor-Robinson D: The role of 
bacterial vaginosis, aerobic vaginitis, abnor-
mal vaginal f lora and the risk of preterm 
birth. BJOG 2010; 117: 119–120. 
 7 Andrade-Rocha FT: Ureaplasma urealyti-
cum and  Mycoplasma hominis in men at-
tending for routine semen analysis: preva-
lence, incidence by age and clinical settings, 
influence on sperm characteristics, relation-
ship with the leukocyte count and clinical 
value. Urol Int 2003; 71: 377–381. 
 8 Cohen CR, Manhart LE, Bukusi EA, et al: 
Association between  Mycoplasma genitali-
um and acute endometritis. Lancet 2002; 359: 
 765–766. 
 9 Svenstrup HF, Fedder J, Kristoffersen SE, et 
al:  Mycoplasma genitalium, Chlamydia tra-
chomatis, and tubal factor infertility – a pro-
spective study. Fer Steril 2008; 90: 513–520. 
 10 Workowski KA, Berman SM, Douglas JM: 
Emerging antimicrobial resistance in  Neis-
seria gonorrhoeae: urgent need to strengthen 
prevention strategies. Ann Intern Med 2008; 
 148: 606–613. 
 11 Weidner W, Krause W, Ludwig M: Relevance 
of male accessory gland infection for subse-
quent fertility with special focus on prostati-
tis. Hum Reprod Update 1999; 5: 421–432. 
 12 Tian YH, Xiong JW, Hu L, et al:  Candida al-
bicans and filtrates interfere with human 
spermatozoal motility and alter the ultra-
structure of spermatozoa: an in vitro study. 
Int J Androl 2007; 30: 421–429. 
 13 Tang YW, Himmelfarb E, Willis M, Stratton 
CW: Characterization of three  Staphylococ-
cus aureus isolates from a 17-year-old female 
who died of tampon-related toxic shock syn-
drome. J Clin Microbiol 2010; 48: 1974–1977. 
 14 Ellies E, Vallée F, Mari A, Silva S, Bauriaud 
R, Fourcade O, Genestal M: Toxic shock syn-
drome consecutive to the presence of vaginal 
tampon for menstruation regressive after 
early haemodynamic optimization and acti-
vated protein C infusion. Ann Fr Anesth Re-
anim 2009; 28: 91–95. 
 15 Parsonnet J, Hansmann MA, Delaney ML, 
Modern PA, Dubois AM, Wieland-Alter W, 
Wissemann KW, Wild JE, Jones MB, Sey-
mour JL, Onderdonk AB: Prevalence of toxic 
shock syndrome toxin 1-producing  Staphy-
lococcus aureus and the presence of antibod-
ies to this superantigen in menstruating 
women. J Clin Microbiol 2005;  43:  4628–
4634. 
 16 Eschenbach DA, Hillier S, Critchlow C, et al: 
Diagnosis and clinical manifestations of 
bacterial vaginosis. Am J Obstetr Gynecol 
1988; 158: 879–828. 
 17 Hillier S, Holmes KK: Bacterial Vaginosis. 
New York, McGraw-Hill, 1999. 
 18 Hoyme UB, Eschenbach DA: Bakterielle 
Vaginose. Dtsch Med Wochenschr 1985; 110: 
 349–352. 
 19 Harmanli OH, Cheng GY, Nyirjesy P, et al: 
Urinary tract infections in women with bac-
terial vaginosis. Obstetr Gynecol 2000; 95: 
 710–712. 
 20 Hillebrand L, Harmanli OH, Whiteman V, et 
al: Urinary tract infections in pregnant 
women with bacterial vaginosis. Am J Ob-
stetr Gynecol 2002; 186: 916–917. 
 21 Sobel JD: Bacterial vaginosis. Annu Rev Med 
2000; 51: 349–356. 
 22 Spinillo A, Capuzzo E, Gulminetti R, et al: 
Prevalence of and risk factors for fungal vag-
initis caused by non-albicans species. Am J 
Obstet Gynecol 1997; 176: 138–141. 
 23 Wølner-Hanssen P, Krieger JN, Stevens CE, 
et al: Clinical manifestations of vaginal 
trichomoniasis. JAMA 1989; 261: 571–576. 
 24 Joesoef MR, Schmid GP, Hillier SL: Bacterial 
vaginosis: review of treatment options and 
potential clinical indications for therapy. 
Clin Infect Dis 1999; 28(suppl 1):S57–S65. 
 25 Colsky AS, Kirsner RS, Kerdel FA: Analysis 
of antibiotic susceptibilities of skin wound 
flora in hospitalized dermatology patients: 
the crisis of antibiotic resistance has come to 
the surface. Arch Dermatol 1998; 134: 1006–
1009. 
 26 Fischbach F, Petersen EE, Weissenbacher 
ER, et al: Efficacy of clindamycin vaginal 
cream versus oral metronidazole in the 
treatment of bacterial vaginosis. Obstetr Gy-
necol 1993; 82: 405–410. 
 27 Paavonen J, Mangioni C, Martin MA, et al: 
Vaginal clindamycin and oral metronida-
zole for bacterial vaginosis: a randomized 
trial. Obstetr Gynecol 2000; 96: 256–260. 
 28 Shubair M, Stanek R, White S, et al: Effects 
of chlorhexidine gluconate douche on nor-
mal vaginal f lora. Gynecol Obstet Invest 
1992; 34: 229–233. 
 29 Grassi TF, Camargo EA, Salvadori DMF, et 
al: DNA damage in multiple organs after ex-
posure to chlorhexidine in Wistar rats. Int J 
Hyg Environ Health 2007; 210: 163–167. 
 30 Sonis ST, Clark WB, Shklar G: Chlorhexi-
dine-induced lingual keratosis and dysplasia 
in rats. J Periodontol 1978; 49: 585–591. 
 31 Bassetti C, Kallenberger A: Influence of 
chlorhexidine rinsing on the healing of oral 
mucosa and osseous lesions. J Clin Periodon-
tol 1980; 7: 443–456. 
 32 Paunio KU, Knuttila M, Mielitynen H: The 
effect of chlorhexidine gluconate on the for-
mation of experimental granulation tisue. J 
Periodontol 1978; 49: 92–95. 
 33 Lee TH, Hu CC, Lee SS, et al: Cytotoxicity of 
chlorhexidine on human osteoblastic cells is 
related to intracellular glutathione levels. Int 
Endod J 2010; 43: 430–435. 
 34 Lessa FC, Aranha AM, Nogueira I, et al: Tox-
icity of chlorhexidine on odontoblast-like 
cells. J Appl Oral Sci 2010; 18: 50–58. 
 35 Gavlick WK, Davis PK: Gas chromatograph-
ic determination of p-chloroaniline in a 
chlorhexidine digluconate-containing alco-
hol foam surgical scrub product. J AOAC Int 
1994; 77: 583–586. 
 36 Hübner NO, Kramer A: Review on the effi-
cacy, safety and clinical applications of poli-
hexanide, a modern wound antiseptic. Skin 
Pharmacol Physiol 2010; 23: 17–27. 
 37 Hübner NO, Siebert J, Kramer A: Octenidine 
dihydrochloride, a modern antiseptic for 
skin, mucous membranes and wounds. Skin 
Pharmacol Physiol 2010; 23: 244–258. 
 38 Kramer A, Roth B: Polihexanid; in Kramer 
A, Assadian O (eds): Wallhäussers Praxis der 
Sterilisation, Desinfektion, Antiseptik und 
Konservierung. Stuttgart, Thieme, 2008, pp 
789–793. 
 39 Hansmann F, Kramer A, Ohgke H, et al: 
Polyhexamethylbiguanid (PHMB) as preop-
erative antiseptic for cataract surgery. Oph-
thalmologe 2004; 101: 377–383. 
 Koban et al.  Skin Pharmacol Physiol 2012;25:298–304  304
 40 Hansmann F, Kramer A, Ohgke H, et al: La-
vasept as an alternative to PVP-iodine as a 
preoperative antiseptic in ophthalmic sur-
gery: randomized, controlled, prospective 
double-blind trial. Ophthalmologe 2005; 
 102: 1043–1046. 
 41 Gerli SDR, Di Renzo GC: A new approach for 
the treatment of bacterial vaginosis: use of 
polyhexamethylene biguanide – a prospec-
tive, randomized study. Eur Rev Med Phar-
macol Sci 2003; 7: 127–130. 
 42 Müller G, Kramer A: Biocompatibility index 
of antiseptic agents by parallel assessment of 
antimicrobial activity and cellular cytotox-
icity. J Antimicrob Chemother 2008;  61: 
 1281–1287. 
 43 Kramer A, Daeschlein G, Kammerlander G, 
et al: Konsensusempfehlung zur Auswahl 
von Wirkstoffen für die Wundantiseptik. 
Hyg Med 2004; 29: 147–157. 
 44 Gabriel GJ, Som A, Madkour AE, Eren T, 
Tew GN: Infectious disease: connecting in-
nate immunity to biocidal polymers. Mater 
Sci Eng R Rep 2007; 57: 28–64. 
 45 Gilbert P, Moore LE: Cationic antiseptics: di-
versity of action under a common epithet. J 
Appl Microbiol 2005; 99: 703–715. 
 46 Ikeda T, Ledwith A, Bamford CH, et al: In-
teraction of a polymeric biguanide biocide 
with phospholipid membranes. Biochim 
Biophys Acta 1984; 769: 57–66. 
 47 Yasuda K, Ohmizo C, Katsu T: Potassium 
and tetraphenylphosphonium ion-selective 
electrodes for monitoring changes in the 
permeability of bacterial outer and cytoplas-
mic membranes. J Microbiol Methods 2003; 
 54: 111–115. 
 48 Ikeda T, Tazuke S, Watanabe M: Interaction 
of biologically active molecules with phos-
pholipid membranes. 1. Fluorescence depo-
larization studies on the effect of polymeric 
biocide bearing biguanide groups in the 
main chain. Biochim Biophys Acta 1983; 735: 
 380–386. 
 49 Ikeda T, Tazuke S, Bamford C, et al: Spectro-
scopic studies on the interaction of polymer-
ic in-chain biguanide biocide with phospho-
lipid membranes as probed by 8-anilinon-
aphthalene-1-sulfonate. Bull Chem Soc Jpn 
1985; 58: 705–709. 
 50 Rosin M, Welk A, Kocher T, et al: The effect 
of a polyhexamethylene biguanide mouth-
rinse compared to an essential oil rinse and 
a chlorhexidine rinse on bacterial counts and 
4-day plaque regrowth. J Clin Periodontol 
2002; 29: 392–399. 
 51 Gilbert P, Das JR, Jones MV, et al: Assess-
ment of resistance towards biocides follow-
ing the attachment of micro-organisms to, 
and growth on, surfaces. J Appl Microbiol 
2001; 91: 248–254. 
 52 Hammann A, Huebner NO, Bender C, et al: 
Antiseptic efficacy and tolerance of tissue-
tolerable plasma compared with two wound 
antiseptics on artificially bacterially con-
taminated eyes from commercially slaugh-
tered pigs. Skin Pharmacol Physiol 2010; 23: 
 328–332. 
 53 Müller G, Kramer A: Effect of selected, 
wound antiseptics on adult articular carti-
lage (bovine sesamoid bone) in the presence 
of  Escherichia coli and  Staphylococcus aure-
us. J Orthop Res 2005; 23: 127–133. 
 54 Koburger T, Hübner NO, Braun M, et al: 
Standardized comparison of antiseptic effi-
cacy of triclosan, PVP-iodine, octenidine di-
hydrochloride, polyhexanide and chlorhexi-
dine digluconate. J Antimicrob Chemother 
2010; 65: 1712–1719. 
 55 Minozzi M, Gerli S, Di Renzo GC, et al: The 
efficacy and safety of a single dose of poly-
hexamethylene biguanide gynaecologic so-
lution versus a seven-dose regimen of vagi-
nal clindamycin cream in patients with bac-
terial vaginosis. Eur Rev Med Pharmacol Sci 
2008; 12: 59–65. 
 56 Valluri S, Fleming TP, Laycock KA, et al: In 
vitro and in vivo effects of polyhexameth-
ylene biguanide against herpes simplex virus 
infection. Cornea 1997; 16: 556–559. 
 57 Krebs FC, Miller SR, Ferguson ML, et al: 
Polybiguanides, particularly polyethylene 
hexamethylene biguanide, have activity 
against human immunodeficiency virus 
type 1. Biomed Pharmacother 2005; 59: 438–
445. 
 58 Fiscella RG, Moshifar M, Messick CR, et al: 
Polyhexamethylene biguanide (PHMB) in 
the treatment of experimental  Fusarium ke-
ratomycosis. Cornea 1997; 16: 447–449. 
 59 Roth B, Baltzer K: Preliminary treatment of 
the recipient site and healing of open spon-
giosa transplant in post-traumatic osteitis. 
Helv Chir Acta 1989; 56: 571–572. 
 60 Roth B, Baltzer K: Preventive intraoperative 
irrigation in wound management with Lava-
sept: report of experiences with 1,610 cases. 
Z Unfallchir Versicherungsmed 1990;  83: 
 224–226. 
 61 Marelli G, Papaleo E, Origoni M, et al: Poly-
hexamethylene biguanide for treatment of 
external genital warts: a prospective, double-
blind, randomized study. Eur Rev Med Phar-
macol Sci 2005; 9: 369–372. 
 62 Kampf G, Hofer M, Wendt C: Efficacy of 
hand disinfectants against vancomycin-re-
sistant enterococci in vitro. J Hosp Infect 
1999; 42: 143–150. 
 63 Russell AD: Plasmids and bacterial resis-
tance to biocides. J Appl Microbiol 1997; 83: 
 155–165. 
 64 Tattawasart U, Maillard JY, F, et al: Develop-
ment of resistance to chlorhexidine diacetate 
and cetylpyridinium chloride in  Pseudomo-
nas stutzeri and changes in antibiotic sus-
ceptibility. J Hosp Infect 1999; 42: 219–229. 
 65 Yamamoto T, Tamura Y, Yokota T: Antisep-
tic and antibiotic resistance plasmid in 
 Staphylococcus aureus that possesses ability 
to confer chlorhexidine and acrinol resis-
tance. Antimicrob Agents Chemother 1988; 
 32: 932–935. 
 66 Lambert RJ, Joynson J, Forbes B: The rela-
tionships and susceptibilities of some indus-
trial, laboratory and clinical isolates of  Pseu-
domonas aeruginosa to some antibiotics and 
biocides. J Appl Microbiol 2001; 91: 972–984. 
 67 Moore LE, Ledder RG, Gilbert P, et al: In vi-
tro study of the effect of cationic biocides on 
bacterial population dynamics and suscepti-
bility. Appl Environ Microbiol 2008;  74: 
 4825–4834. 
 68 Koburger T, Müller G, Eisenbeiss W, et al: 
Microbicidal activity of polihexanide. GMS 
Krankenhaushyg Interdiszip 2007; 2:Doc44. 
 
